| Title |
Vorasidenib, a Dual Inhibitor of Mutant IDH1/2, in Recurrent or Progressive Glioma; Results of a First-in-Human Phase I TrialVorasidenib in Recurrent or Progressive Glioma
|
|---|---|
| Published in |
Clinical Cancer Research, June 2021
|
| DOI | 10.1158/1078-0432.ccr-21-0611 |
| Pubmed ID | |
| Authors |
Ingo K. Mellinghoff, Marta Penas-Prado, Katherine B. Peters, Howard A. Burris, Elizabeth A. Maher, Filip Janku, Gregory M. Cote, Macarena I. de la Fuente, Jennifer L. Clarke, Benjamin M. Ellingson, Saewon Chun, Robert J. Young, Hua Liu, Sung Choe, Min Lu, Kha Le, Islam Hassan, Lori Steelman, Shuchi S. Pandya, Timothy F. Cloughesy, Patrick Y. Wen |
X Demographics
The data shown below were collected from the profiles of 40 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 10 | 25% |
| India | 5 | 13% |
| Germany | 2 | 5% |
| United Kingdom | 2 | 5% |
| Canada | 2 | 5% |
| Colombia | 1 | 3% |
| Brazil | 1 | 3% |
| France | 1 | 3% |
| Australia | 1 | 3% |
| Other | 0 | 0% |
| Unknown | 15 | 38% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 23 | 57% |
| Scientists | 10 | 25% |
| Practitioners (doctors, other healthcare professionals) | 5 | 13% |
| Science communicators (journalists, bloggers, editors) | 2 | 5% |
Mendeley readers
The data shown below were compiled from readership statistics for 76 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 76 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 12 | 16% |
| Student > Ph. D. Student | 9 | 12% |
| Student > Master | 6 | 8% |
| Student > Doctoral Student | 3 | 4% |
| Other | 2 | 3% |
| Other | 7 | 9% |
| Unknown | 37 | 49% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 15 | 20% |
| Biochemistry, Genetics and Molecular Biology | 9 | 12% |
| Agricultural and Biological Sciences | 4 | 5% |
| Neuroscience | 4 | 5% |
| Mathematics | 1 | 1% |
| Other | 5 | 7% |
| Unknown | 38 | 50% |
Attention Score in Context
This research output has an Altmetric Attention Score of 139. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 05 October 2023.
All research outputs
#301,353
of 25,621,213 outputs
Outputs from Clinical Cancer Research
#130
of 13,278 outputs
Outputs of similar age
#8,616
of 461,303 outputs
Outputs of similar age from Clinical Cancer Research
#3
of 168 outputs
Altmetric has tracked 25,621,213 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 98th percentile: it's in the top 5% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 13,278 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 11.8. This one has done particularly well, scoring higher than 99% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 461,303 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 98% of its contemporaries.
We're also able to compare this research output to 168 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 98% of its contemporaries.